อุบัติการณ์และปัจจัยที่มีผลต่อการบรรลุเป้าหมายในการรักษาผู้ป่วยโรคเกาต์ที่ได้รับยาอัลโลพูรินอล

Naphaporn Maneechai; Prapassara Sirikarn; Saovanee  Benjamanukol

Authors

Naphaporn Maneechai Master of Public Health Student in Biostatistics, Faculty of Public Health, Khon Kaen University
Prapassara Sirikarn Assistant Professor, Department of Epidemiology and Biostatistics, Faculty of Public Health, Khon Kaen University
Saovanee Benjamanukol Rheumatologist, Department of Medicine, Banphaeo General Hospital

Keywords:

Uric acid, Allopurinol, Gout

Abstract

This retrospective cohort study aimed to investigate the incidence and factors associated with achieving treatment targets in gout patients receiving allopurinol. A total of 401 patients were included, all of whom received allopurinol at the outpatient rheumatology clinic of Banphaeo General Hospital between 2012 and 2023. The inclusion date and initiation of follow-up were defined as the date the patient first received allopurinol, starting on July 1, 2012. Patient enrollment ended on December 31, 2023, and follow-up continued for one year after allopurinol initiation, with the final follow-up date being December 31, 2024. The characteristics of the sample were described by mean, standard deviation, frequency, and percentage. A modified Poisson regression model was used to investigate the association between factors and the achievement of the treatment goal.
The results showed that the incidence of achieving the treatment target within one year was 58.1% (95% CI: 53.2–62.9). Baseline serum uric acid level was the factor influencing the achievement of treatment targets in gout patients receiving allopurinol. Patients with a very high baseline uric acid level (> 9 mg/dL) were 23% less likely to achieve the treatment target compared to those with high baseline levels ( 6 to 9 mg/dL) (RR = 0.77, 95%CI: 0.64-0.93). Therefore, closely monitoring of serum uric acid levels and appropriate dose adjustment are crucial for successful treatment outcomes in gout patients.

References

Borghi, C., & Perez-Ruiz, F. (2016). Urate lowering therapies in the treatment of gout: A systematic review and meta-analysis. European Review for Medical and Pharmacological Sciences, 20(5), 983-992.

Cairns, I., Lindsay, K., Dalbeth, N., Díaz-Torné, C., Antònia Pou, M., Rodríguez Diez, B., … Taylor, W. J. (2020). The impact of gout as described by patients, using the lens of The International Classification of Functioning, Disability and Health (ICF): a qualitative study. BMC Rheumatology, 4(1), 50. https://doi.org/10.1186/s41927-020-00147-2

Chaiamnuay, P., Darmawan, J., Muirden, K. D., & Assawatanabodee, P. (1998). Epidemiology of rheumatic disease in rural Thailand: a WHO-ILAR COPCORD study. Community Oriented Programme for the Control of Rheumatic Disease. The Journal of Rheumatology, 25(7), 1382-1387.

Chiowchanwisawakit, P., Charoenhongthong, K., Katchamart, W., & Srinonprasert, V. (2016). AB0825 survey on management of gout and hyperuricemia among Thai physicians. Annals of the Rheumatic Diseases, 75 (Suppl 2), 1185. https://doi.org/10.1136/annrheumdis-2016-eular.3465

Corbett, E. J. M., Pentony, P., & McGill, N. W. (2017). Achieving serum urate targets in gout: An audit in a gout-oriented rheumatology practice. International Journal of Rheumatic Diseases, 20(7), 894-897. https://doi.org/10.1111/1756-185X.13032

FitzGerald, J. D., Dalbeth, N., Mikuls, T., Brignardello-Petersen, R., Guyatt, G., Abeles, A. M., . . . Neogi, T. (2020). 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care & Research, 72(6), 744-760. https://doi.org/10.1002/acr.24180

Fu, T., Cao, H., Yin, R., Zhang, L., Zhang, Q., Li, L., … Gu, Z. (2018). Depression and anxiety correlate with disease-related characteristics and quality of life in Chinese patients with gout: a case-control study. Psychology, Health & Medicine, 23(4), 400-410. https://doi.org/10.1080/13548506.2017.1378819

Hatoum, H., Khanna, D., Lin, S., Akhras, K. S., Shiozawa, A., & Khanna, P. (2014). Achieving serum urate goal: A comparative effectiveness study between allopurinol and febuxostat. Postgraduate Medicine, 126(2), 65–75. https://doi.org/10.3810/pgm.2014.03.2741

Hosmer, D. W., & Lemeshow, S. (1989). Applied logistic regression, Second Edition. Retrieved from https://api.semanticscholar.org/CorpusID:198489226

Neogi, T., Jansen, T. L. T. A., Dalbeth, N., Fransen, J., Schumacher, H. R., Berendsen, D., … Taylor, W. J. (2015). 2015 Gout classification criteria: an American College of Rheumatology/ European League Against Rheumatism collaborative initiative. Annals of the Rheumatic Diseases, 74(10), 1789. https://doi.org/10.1136/annrheumdis-2015-208237

Richette, P., Doherty, M., Pascual, E., Barskova, V., Becce, F., Castañeda-Sanabria, J., … Bardin, T. (2017). 2016 updated EULAR evidence-based recommendations for the management of gout. Annals of the Rheumatic Diseases, 76(1), 29. https://doi.org/10.1136/annrheumdis-2016-209707

Singh, J. A., & Gaffo, A. (2020, June 1). Gout epidemiology and comorbidities. Seminars in Arthritis and Rheumatism, Vol. 50, pp. S11-S16. W.B. Saunders. https://doi.org/10.1016/j.semarthrit.2020.04.008

Singh, J. A., Yang, S., & Saag, K. G. (2020). Factors influencing the effectiveness of allopurinol in achieving and sustaining target serum urate in a US Veterans Affairs Gout Cohort. The Journal of Rheumatology, 47(3), 449. https://doi.org/10.3899/jrheum.190522

Wood, R., Fermer, S., Ramachandran, S., Baumgartner, S., & Morlock, R. (2016). Patients with gout treated with conventional urate-lowering therapy: Association with disease control, health-related quality of life, and work productivity. The Journal of Rheumatology, 43(10), 1897. https://doi.org/10.3899/jrheum.151199

Zhang, J., & Yu, K. F. (1998). What’s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA, 280(19), 1690-1691. https://doi.org/10.1001/jama.280.19.1690